Correction: Standards Without Labs: Drug Development in the Psychedelic Underground
Authors
John Bailey
Joanna Kempner
Abstract
This article details a correction to: Bailey, J. and Kempner, J., 2022. Standards Without Labs: Drug Development in the Psychedelic Underground. Citizen Science: Theory and Practice, 7(1), p.41. DOI: http://doi.org/10.5334/cstp.527
Bailey and Kempner () mention that “the patent issued for the use of psilocybin as a therapy for cluster headache by the US Patent and Trademark Office fails to include the names of anyone affiliated with Clusterbusters ().” Sewell () draws upon Clusterbusters’ experience using psilocybin without citation but does not attempt to patent this knowledge. Schindler and D’Souza () is an example of a patent application filed for using psilocybin as a therapy for cluster headache that failed to include the names of anyone affiliated with Clusterbusters.
Competing interests
The authors received a small grant from Porta Sophia, a non-profit psychedelic prior art library that submitted a third-party preissuance to the United States Patent and Trademark Office (USPTO) in reference to the application, US Pat. App. Ser. No. 17/168,638 entitled “Psychedelic Treatment for Headache Disorders.”
References
Bailey, J and Kempner, J. 2022. Standards Without Labs: Drug Development in the Psychedelic Underground. Citizen Science: Theory and Practice, 7(1): 41. DOI: https://doi.org/10.5334/cstp.527
